Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915951 · ClinicalTrials.gov registry record · Phase 2
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 20
- Study locations
NCT03915951 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Pfizer. The registered enrollment target is 98 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT03915951, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.
Conditions Studied
Interventions
- DRUG binimetinib
- DRUG encorafenib
Study Locations (20)
Florida
- Florida Cancer Specialist - Altamonte Springs
- Florida Cancer Specialists - Bonita Springs
- Florida Cancer Specialist - Brandon
- Florida Cancer Specialists - Cape Coral
- Florida Cancer Specialist - Clearwater
- Florida Cancer Specialists - Fleming Island
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialist - Gainesville
- Florida Cancer Specialists - Largo
- Florida Cancer Specialist - Lecanto
- Florida Cancer Specialists - Naples
- Florida Cancer Specialist - Ocala
- Florida Cancer Specialist - Orange City
- Florida Cancer Specialist - Orlando
Arizona
- Yuma Regional Medical Center Cancer Center - Yuma
- Yuma Regional Medical Center Ophthalmology - Yuma
- Yuma Regional Medical Center - Yuma
California
- UCLA Stein Eye Center Santa Monica (OPH) - Santa Monica
- UCLA Hematology/Oncology - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2019-06-04 |
| Est. Completion | 2025-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03915951
The ClinicalTrials.gov registry entry for NCT03915951 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which binimetinib is the first listed.
NCT03915951 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT03915951 about?
NCT03915951 is a clinical study titled "An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer". This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who h...
What is the current status of trial NCT03915951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2019-06-04. Estimated completion is 2025-10-03.
What conditions does trial NCT03915951 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03915951?
The interventions under investigation include: binimetinib (DRUG), encorafenib (DRUG).
Who is sponsoring clinical trial NCT03915951?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03915951 being conducted?
This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.